Latest news with #Mixtard
Time of India
19-05-2025
- Health
- Time of India
Domestic drug companies in a sweet spot as global players look beyond insulin
Leading Indian drugmakers such as Eris Lifesciences , Lupin , Mankind and Wockhardt are making strong inroads into the country's insulin market-long dominated by multinationals such as Novo Nordisk , Sanofi and Eli Lilly. A combination of investments in affordable insulin , deeper market penetration, and a sharp rise in type 1 diabetes cases has helped domestic companies gain a foothold in this segment, according to industry insiders. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 10년 발톱무좀, 정확히 6개월 걸렸습니다! (사실주의) 홈시네라이프 더 알아보기 Undo Indian companies accounted for ₹1,089 crore, or about 25%, of India's ₹4,404-crore insulin market in the 12 months ended April, as per data from market researcher PharmaTrac. Domestic players grew 13% year on year, driven by their own products and strategic partnerships-double the growth rate of multinational competitors. "Indian pharma companies have invested in biologics and biosimilars, giving them the technical capability to produce insulin at scale," said Rajeev Juneja, managing director and vice chairman of Mankind Pharma . "India's cost-effective manufacturing infrastructure enables it to produce insulin more affordably than many Western competitors, making it more accessible to patients." Live Events With global companies such as Novo Nordisk and Eli Lilly steadily shifting their focus from insulin to glucagon-like peptide-1 (GLP-1) medications, there is significant scope for domestic players, experts said. "MNCs who dominate the insulin market are gradually shifting focus to the anti-obesity market, thus creating space for Indian companies to slowly gain ground in the insulins segment," said Sheetal Sapale, VP, commercial, at PharmaTrac. "Partnerships with MNCs as well as Indian biologics companies give an upper hand to the Indian players," she added. Novo Nordisk, the maker of semaglutide blockbusters Ozempic and Wegovy, recently said it is planning to retire a range of its human premix insulin brand Mixtard available in easy-to-use disposable pen and cartridge forms by the end of this year. Eli Lilly has given its insulin marketing rights to Cipla and is focusing on anti-obesity. Last year, Lupin acquired the Huminsulin brand from Eli Lilly to boost its anti-diabetes drugs portfolio. "Since some of these insulins have been withdrawn by MNCs, Indian companies are now beginning to get the bigger share of the market," said V Mohan, chairman of Dr Mohan's Diabetes Specialities Centre, Chennai. The annual incidence of type 1 diabetes in India is estimated to be 4.9 cases per 100,000 population, particularly among children below 20 years of age. This translates to about 860,423 individuals with type 1 diabetes. "Insulin forms the backbone of diabetes treatment. The increasing cases of Type 1 diabetes and even long-term Type 2 diabetes is creating a huge market opportunity for Indian companies that can give good quality insulin at an affordable price," said Aasim Maldar, consultant - endocrinologist and diabetologist at Mumbai's PD Hinduja Hospital. Insulin is also administered by hospitals during pregnancy, operations, etc, when there could be a sudden spike in sugar levels. "Many Indian companies had a diabetic portfolio for a long time, if not insulin. So, it will not be difficult for them to strengthen their presence," Maldar said.
Time of India
25-04-2025
- Business
- Time of India
Novo Nordisk to continue India's largest insulin brand Mixtard supply in vials
Representative image Novo Nordisk has stated that its flagship insulin brand Mixtard will continue to be available in India in vial form, even as the company phases out other delivery formats such as Penfill cartridges. The announcement comes amid widespread concern over the discontinuation of some of the country's most-used insulin products. Responding to TOI reports that it was withdrawing Mixtard—India's top-selling insulin brand with annual sales of over Rs 800 crore, Novo Nordisk said in a statement. 'In order to meet increasing patient demand and ensure a stable supply of our medicines, we have decided to consolidate our insulin portfolio. This will create space needed in our global manufacturing network,' 'Hence, in this process, we are phasing out the Penfill. We acknowledge that this will be disruptive to people living with diabetes who rely on our treatments. However, by doing this now, we will increase the number of patients we reach with our insulin portfolio by many millions in the next decade," it added. This comes after reports that the Danish drugmaker was discontinuing Human Mixtard—India's largest-selling insulin brand—and other older-generation insulins from the market. The TOI report noted that Human Mixtard, a Rs 800 crore brand despite being under price control, along with products like Actrapid, Insulatard, Insulin Detemir, Levemir, and Xultophy, would no longer be available in popular delivery formats such as pre-filled pens and cartridges (Penfill and FlexPen). Read report: Novo Nordisk to phase out country's largest insulin brand The Danish pharmaceutical giant reassured patients that the insulin, along with other human insulins like Actrapid and Insulatard, will still be accessible in vials across India. These vials are administered through traditional syringes. According to documents cited in the earlier report, Novo Nordisk had informed its marketing partner Abbott India that the products would be withdrawn once current stocks were exhausted, a process expected to take around six months. The move is reportedly part of the company's global strategy to shift focus toward newer, more profitable treatments such as Ozempic and Wegovy , which it plans to introduce in the Indian market this year. As part of this shift, earlier-generation insulin products are being gradually phased out worldwide. Stay informed with the latest business news, updates on bank holidays and public holidays . Master Value & Valuation with ET! Learn to invest smartly & decode financials. Limited seats at 33% off – Enroll now!
Time of India
25-04-2025
- Health
- Time of India
Novo Nordisk to continue largest insulin brand Mixtard supply in vials amid penfill device phase-out
Representative image Novo Nordisk has stated that its flagship insulin brand Mixtard will continue to be available in India in vial form, even as the company phases out other delivery formats such as Penfill cartridges, in a response to a Times of India report. The announcement comes amid widespread concern over the discontinuation of some of the country's most-used insulin products. Responding to reports that it was withdrawing Mixtard—India's top-selling insulin brand with annual sales of over Rs 800 crore—the Danish pharmaceutical giant reassured patients that the insulin, along with other human insulins like Actrapid and Insulatard, will still be accessible in vials across India. These vials are administered through traditional syringes. 'In order to meet increasing patient demand and ensure a stable supply of our medicines, we have decided to consolidate our insulin portfolio. This will create space needed in our global manufacturing network,' Novo Nordisk said in a statement. 'Hence, in this process, we are phasing out the Penfill. We acknowledge that this will be disruptive to people living with diabetes who rely on our treatments. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play this game for 3 minutes, if you own a mouse Undo However, by doing this now, we will increase the number of patients we reach with our insulin portfolio by many millions in the next decade. ' This comes after reports that the Danish drugmaker was discontinuing Human Mixtard—India's largest-selling insulin brand—and other older-generation insulins from the market. The TOI report noted that Human Mixtard, a Rs 800 crore brand despite being under price control, along with products like Actrapid, Insulatard, Insulin Detemir, Levemir, and Xultophy, would no longer be available in popular delivery formats such as pre-filled pens and cartridges (Penfill and FlexPen). Read report: Novo Nordisk to phase out country's largest insulin brand According to documents cited in the earlier report, Novo Nordisk had informed its marketing partner Abbott India that the products would be withdrawn once current stocks were exhausted, a process expected to take around six months. The move is reportedly part of the company's global strategy to shift focus toward newer, more profitable treatments such as Ozempic and Wegovy , which it plans to introduce in the Indian market this year. As part of this shift, earlier-generation insulin products are being gradually phased out worldwide. Stay informed with the latest business news, updates on bank holidays and public holidays . Master Value & Valuation with ET! Learn to invest smartly & decode financials. Limited seats at 33% off – Enroll now!
Time of India
22-04-2025
- Business
- Time of India
Novo Nordisk to phase out key drug, insulin cos spot big biz opportunity
As Novo Nordisk prepares to phase out some forms of its human premix insulin brand Mixtard-a move seen overlapping with its planned launch of weight-loss drug Wegovy in India-other top insulin makers are rushing to ramp up production capacity to bridge the potential demand-supply gap the move is expected to create, said top company executives. The Danish pharma major, the maker of semaglutide blockbusters Ozempic and Wegovy, is planning to retire a range of insulin formulations available in easy-to-use disposable pen and cartridge forms by the end of this year. This would include human insulin in penfill and flexpen, including Mixtard 30 Penfill and Flexpen, Actrapid Penfill and Flexpen, Insulatard Penfill and Flexpen, and Mixtard 50 Penfill over the next six months. It will also phase out insulin brand Levemir in FlexPen and Xultophy FlexTouch (Insulin + GLP1). The company recently informed Abbott India about this planned phase-out, according to a document accessed by ET. Abbott is the marketing partner for Novo's insulin. Confirming the development, a Novo Nordisk spokesperson said, "In order to meet increasing patient demand and ensure a stable supply of our medicines, we have decided to consolidate our insulin portfolio, as this will create space needed in our global manufacturing network. Hence, in this process, we are phasing out the penfill." However, the company said it is not discontinuing Mixtard in India and "it will continue to be available in vials". The company did not provide any details on specific brands. "Along with it, other forms of insulins, including human insulins from Novo Nordisk, will continue to be available in vials and devices for patients across India," the spokesperson said. "With the decision, we strive not to leave any patients without alternative treatment options, either from Novo Nordisk or other companies. It is important to us that the transition to other devices or treatment options is as smooth as possible for patients." The phasing out of the penfill Mixtard creates an opportunity for other human premix insulin makers such as Lupin , Eris, Eli Lilly, Wockhardt and Cadila , said industry insiders. Amit Bakshi, MD, Eris Lifesciences , which is ramping up capacity to produce penfill insulin said, "Our strategy is to make sure how we are available through and through and how we can ramp up manufacturing." However, according to him the transition phase may be a "small level of emergency", as a lot of hoarding has been happening in the last couple of months after the news has been out, with several large stockists and patients increasing their stock. "We may not be able to take on all of the demand immediately but are planning to take 60-70% of it."
